Gilead sets list price of remdesivir in Covid-19 for U.S. commercial payers, developed countries
Source: https://ift.tt/31y6ttD
The company determined a price of $520 per vial for U.S. payers and $390 for government payers outside the U.S., the latter price being designed to avoid the need for country-by-country pricing negotiations, CEO Daniel O’Day wrote in an open letter.
Source: https://ift.tt/31y6ttD
0 Comments